Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

BMY Bristol Myers Squibb Co

44,68

1,01 (2,31%)

10 Mai 2024 - Fermé

Retardé de 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Bristol Myers Squibb (NYSE:BMY)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024

Plus de graphiques de la Bourse Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024

Plus de graphiques de la Bourse Bristol Myers Squibb

Actualités Bristol Myers Squibb Co

Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Mardi 7 Mai 2024 ( il y a 3 jours) • Business Wire

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
Lundi 6 Mai 2024 ( il y a 4 jours) • Business Wire

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Mercredi 1 Mai 2024 ( il y a 1 semaine) • GlobeNewswire Inc.

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Lundi 29 Avril 2024 ( il y a 2 semaines) • PR Newswire (US)

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Vendredi 26 Avril 2024 ( il y a 2 semaines) • Business Wire

U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast
Jeudi 25 Avril 2024 ( il y a 2 semaines) • IH Market News

Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Jeudi 25 Avril 2024 ( il y a 2 semaines) • Business Wire

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Mardi 23 Avril 2024 ( il y a 2 semaines) • IH Market News

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
Lundi 22 Avril 2024 ( il y a 3 semaines) • Business Wire

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Lundi 8 Avril 2024 ( il y a 1 mois) • Business Wire

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Samedi 6 Avril 2024 ( il y a 1 mois) • Business Wire

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Vendredi 5 Avril 2024 ( il y a 1 mois) • Business Wire

Plus d'articles sur Bristol Myers Squibb Co

Cie de SaintGobain

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales